Clinical Trial Update: Bioequivalence Study of Raperazole 20mg DR Tabs and PARIET® 20 mg DR Tabs Under Fed Conditions [Phase 4]

View source ↗

Summary

Phase 4 bioequivalence study comparing Raperazole 20 mg sustained-release tablets to PARIET 20 mg sustained-release tablets under fed conditions has completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Diseases

Drugs mentioned

• Pariet (rabeprazole)
• Raperazole (Raperazole)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Gastrointestinal Diseases | Phase 4 | Status: COMPLETED | Results posted: 2018-10-01